BSE filing, NSE: BACPHAR. Summary written from the filing by ALFA Finder's alert engine.
Bacil Pharma Ltd: key numbers
- Share price
- ₹18.40
- Market cap
- ₹26.41 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹1.56 Cr
- P/E (TTM)
- 41.8×Sector 48.7×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bacil Pharma Ltd
All →Bacil Pharma Other Announcement
Bacil Pharma Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.
Bacil Pharma Q2 FY27 Results: Net Loss of ₹0.1 Cr
Bacil Pharma Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
Bacil Pharma Management Change
Mr. Dikshant Singh Panwar has resigned as Whole-Time Company Secretary and Compliance Officer of Bacil Pharma Limited, effective October 8, 2026.
Bacil Pharma Board Meeting Date
Bacil Pharma will hold a board meeting on October 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Bacil Pharma Annual Report
Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.
Bacil Pharma Annual General Meeting
Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.
Other other announcement announcements
All →STL Networks Other Announcement
The Monitoring Agency reported Rs. 2 Crore utilization of Preferential Issue proceeds, with no deviations from objects. The report covers the quarter ending September 30, 2026.
HEG Advanced Materials Other Announcement
HEG Advanced Materials Limited has intimated the exchange regarding the change of its Corporate Identification Number (CIN) following an approved scheme of arrangement.
Sanofi India Other Announcement
Sanofi India issued a communication regarding Tax Deduction at Source (TDS) for the interim dividend declared for FY 2026. Shareholders must update details by November 5, 2026.
Visaka Industries Other Announcement
Visaka Industries informed the exchange about sending reminder letters to shareholders regarding the compulsory transfer of unclaimed dividends and equity shares to the IEPF account.
Arvaya Healthcare Other Announcement
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
AYM Syntex Other Announcement
AYM Syntex's board appointed BSR & Co. LLP as statutory auditor for five years, subject to shareholder approval. Routine auditor appointment; no monetary value involved.
- Execution
- Five consecutive years, from the conclusion of the 44th AGM to the conclusion of the 49th AGM